Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Elanco Animal Health IncELAN · Entity 3457 | Director | November 29, 2024 | December 03, 2024 |
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Senior Vice President | February 15, 2023 | February 17, 2023 |
| IMMUCELL CORP /DE/ICCC · Entity 6837 | Director | April 15, 2026 | April 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Elanco Animal Health Inc
Report date November 29, 2024 · Filed December 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,838 |
Reported balance
After 2024-11-29 transaction · row 1
1 source rowRow 1 · 2024-11-29 · Grant · Acquired 13,838 · Balance 13,838 F1: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.
IDEXX LABORATORIES INC /DE
Report date February 15, 2023 · Filed February 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,379.8492 |
Ending reported balance
After 2023-02-16 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-02-15 · Grant · Acquired 1,000 · Balance 8,379.8492 Row 2 · 2023-02-15 · Sale · Disposed 1,000 · Balance 7,379.8492 F1: Represents the weighted average price of the shares sold ranging from a low of $510.00 to a high of $510.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 3 · 2023-02-16 · Exercise / conversion · Acquired 10 · Balance 7,389.8492 Row 4 · 2023-02-16 · Sale · Disposed 10 · Balance 7,379.8492 |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.54 · Expires 2025-02-13 | Direct | 3,736 |
Reported balance
After 2023-02-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-02-15 · Exercise / conversion · Disposed 1,000 · Balance 3,736 F4: Not applicable. F3: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.54 · Expires 2025-02-13 | Direct | 3,726 |
Reported balance
After 2023-02-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-02-16 · Exercise / conversion · Disposed 10 · Balance 3,726 F4: Not applicable. F3: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. |
| Common StockSEC Table I · non-derivative | Indirectby spouse | 100 |
Reported balance
Holding disclosure · report date 2023-02-15 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 100 F2: The reporting person disclaims beneficial interest of the shares of common stock held by her spouse except to the extent of her pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average price of the shares sold ranging from a low of $510.00 to a high of $510.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F2: The reporting person disclaims beneficial interest of the shares of common stock held by her spouse except to the extent of her pecuniary interest therein.
F3: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
F4: Not applicable.
IMMUCELL CORP /DE/
Report date April 15, 2026 · Filed April 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2036-04-15 | Direct | 17,899 |
Reported balance
After 2026-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-15 · Grant · Acquired 17,899 · Balance 17,899 F1: The stock option vests as follows: 5,966 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares becoming exercisable on April 15, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as follows: 5,966 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares becoming exercisable on April 15, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2022 Filed Feb 17, 2022 00:28 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 371 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004787 · doc1.xml · derivative · entry 10 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,376 Underlying: Common Stock · 371 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F11 · price: Not applicable. F5 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F5 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:28 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 197 | Not disclosed Strike: $505.53 | Not disclosed |
DisclosureSEC source: 0001567619-22-004787 · doc1.xml · derivative · entry 9 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197 Underlying: Common Stock · 197 shares Expires 2032-02-13 F11 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on the fourth anniversary of the date of grant. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:28 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 3,078 | Not disclosed Strike: $505.53 | Not disclosed |
DisclosureSEC source: 0001567619-22-004787 · doc1.xml · derivative · entry 8 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,078 Underlying: Common Stock · 3,078 shares Expires 2032-02-13 F11 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2023. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:28 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 295 | $505.53 | $149,131.35 |
DisclosureSEC source: 0001567619-22-004787 · doc1.xml · nonDerivative · entry 6 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,706.3869 Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:28 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 87 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004787 · doc1.xml · nonDerivative · entry 5 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,001.3869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:28 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 162 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004787 · doc1.xml · nonDerivative · entry 4 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,914.3869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:28 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 181 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004787 · doc1.xml · nonDerivative · entry 3 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,752.3869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:28 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 210 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004787 · doc1.xml · nonDerivative · entry 2 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,571.3869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:28 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 211 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004787 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,361.3869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 19 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2021 and December 31, 2021. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 21:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,256 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001567619-21-016671 · doc1.xml · derivative · entry 3 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,256 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 628 shares on February 14, 2020, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 21:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,256 | $79.54 | $99,902.24 |
DisclosureSEC source: 0001567619-21-016671 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,131.3869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 2,250 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001567619-21-016516 · doc1.xml · derivative · entry 8 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,736 Underlying: Common Stock · 2,250 shares Expires 2025-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,250 | $689.00 | $861,250.00 |
DisclosureSEC source: 0001567619-21-016516 · doc1.xml · nonDerivative · entry 5 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,875.3869 Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,000 | $685.00 | $685,000.00 |
DisclosureSEC source: 0001567619-21-016516 · doc1.xml · nonDerivative · entry 4 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,125.3869 Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 2,250 | $79.54 | $178,965.00 |
DisclosureSEC source: 0001567619-21-016516 · doc1.xml · nonDerivative · entry 3 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,125.3869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 276 | Not disclosed Strike: $64.24 | Not disclosed |
DisclosureSEC source: 0001567619-21-016516 · doc1.xml · derivative · entry 7 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 276 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 138 shares in five annual installments beginning June 1, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 276 | $678.00 | $187,128.00 |
DisclosureSEC source: 0001567619-21-016516 · doc1.xml · nonDerivative · entry 2 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,875.3869 Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 276 | $64.24 | $17,730.24 |
DisclosureSEC source: 0001567619-21-016516 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,151.3869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 9.3869 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 30, 2021. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,000 | $558.44 | $1,116,884.20 |
DisclosureSEC source: 0001567619-21-011455 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,886 Read SEC document |
| May 28, 2021 Filed Aug 31, 2021 21:01 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,000 | $558.44 | $1,116,884.20 |
DisclosureSEC source: 0001567619-21-016515 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,866 F1 · balance_after: Amendment is being filed to correct the number of shares of Issuer common stock held. Read SEC document |
| May 24, 2021 Filed May 26, 2021 21:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,000 | $545.00 | $1,090,000.00 |
DisclosureSEC source: 0001567619-21-011202 · doc1.xml · nonDerivative · entry 2 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,866 Read SEC document |
| May 24, 2021 Filed May 26, 2021 21:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 900 | $549.00 | $494,100.00 |
DisclosureSEC source: 0001567619-21-011202 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,866 Read SEC document |
| May 21, 2021 Filed May 24, 2021 22:15 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,000 | $545.00 | $545,000.00 |
DisclosureSEC source: 0001567619-21-011068 · doc1.xml · nonDerivative · entry 3 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,766 Read SEC document |
| May 20, 2021 Filed May 24, 2021 22:15 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,000 | $540.00 | $540,000.00 |
DisclosureSEC source: 0001567619-21-011068 · doc1.xml · nonDerivative · entry 2 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,766 Read SEC document |
| May 20, 2021 Filed May 24, 2021 22:15 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,000 | $535.00 | $535,000.00 |
DisclosureSEC source: 0001567619-21-011068 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,766 F1 · balance_after: Includes 12 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2021. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 163 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-004328 · doc1.xml · derivative · entry 15 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,005 Underlying: Common Stock · 163 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F12 · price: Not applicable. F11 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F11 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 181 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-004328 · doc1.xml · derivative · entry 14 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,168 Underlying: Common Stock · 181 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F12 · price: Not applicable. F10 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F10 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 210 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-004328 · doc1.xml · derivative · entry 13 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,349 Underlying: Common Stock · 210 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F12 · price: Not applicable. F9 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F9 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 212 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-004328 · doc1.xml · derivative · entry 12 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,559 Underlying: Common Stock · 212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. F12 · price: Not applicable. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 221 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-004328 · doc1.xml · derivative · entry 11 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,771 Underlying: Common Stock · 221 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2017. F12 · price: Not applicable. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2017. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2017. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 345 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-004328 · doc1.xml · derivative · entry 10 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,992 Underlying: Common Stock · 345 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F12 · price: Not applicable. F6 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F6 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 183 | Not disclosed Strike: $544.08 | Not disclosed |
DisclosureSEC source: 0001567619-21-004328 · doc1.xml · derivative · entry 9 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183 Underlying: Common Stock · 183 shares Expires 2031-02-13 F3 · derivative.exercise_price: Closing price of Issuer common stock on the NASDAQ Global Select Market on February 12, 2021. F12 · price: Not applicable. F5 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on the fourth anniversary of the date of grant. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 3,131 | Not disclosed Strike: $544.08 | Not disclosed |
DisclosureSEC source: 0001567619-21-004328 · doc1.xml · derivative · entry 8 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,131 Underlying: Common Stock · 3,131 shares Expires 2021-02-13 F3 · derivative.exercise_price: Closing price of Issuer common stock on the NASDAQ Global Select Market on February 12, 2021. F12 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2022. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 388 | $544.08 | $211,103.04 |
DisclosureSEC source: 0001567619-21-004328 · doc1.xml · nonDerivative · entry 6 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,754 Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 163 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-004328 · doc1.xml · nonDerivative · entry 5 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 181 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-004328 · doc1.xml · nonDerivative · entry 4 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 210 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-004328 · doc1.xml · nonDerivative · entry 3 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 212 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-004328 · doc1.xml · nonDerivative · entry 2 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 221 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-004328 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 43 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 30, 2020, September 30, 2020 and December 31, 2020. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,690 | $301.00 | $809,690.00 |
DisclosureSEC source: 0001567619-20-010835 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,112 F1 · balance_after: Includes 23 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2020. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 182 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-004371 · doc1.xml · derivative · entry 14 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,647 Underlying: Common Stock · 182 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F10 · price: Not applicable. F9 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F9 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 211 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-004371 · doc1.xml · derivative · entry 13 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,829 Underlying: Common Stock · 211 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F10 · price: Not applicable. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 212 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-004371 · doc1.xml · derivative · entry 12 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,040 Underlying: Common Stock · 212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. F10 · price: Not applicable. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 221 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-004371 · doc1.xml · derivative · entry 11 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,252 Underlying: Common Stock · 221 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2017. F10 · price: Not applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2017. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2017. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 188 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-004371 · doc1.xml · derivative · entry 10 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,474 Underlying: Common Stock · 188 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015. F10 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 649 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-004371 · doc1.xml · derivative · entry 9 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,661 Underlying: Common Stock · 649 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F10 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 6,680 | Not disclosed Strike: $288.78 | Not disclosed |
DisclosureSEC source: 0001567619-20-004371 · doc1.xml · derivative · entry 8 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,680 Underlying: Common Stock · 6,680 shares Expires 2030-02-13 F10 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2021. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 290 | $288.78 | $83,746.20 |
DisclosureSEC source: 0001567619-20-004371 · doc1.xml · nonDerivative · entry 6 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,779 Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 182 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004371 · doc1.xml · nonDerivative · entry 5 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 211 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004371 · doc1.xml · nonDerivative · entry 4 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.